AcelRx Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
TLPH
CUSIP
00444T209
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 00444T209 since 12/18/2024, newest first.

Filer % of Class Filed
Rosalind Advisors, Inc. 13G/A Amendment 4
9.9% 8/12/2026
Event 6/30/2026
Lytton Laurence W 13G/A Amendment 2
2.5% 5/15/2026
Event 3/31/2026
Rosalind Advisors, Inc. 13G/A Amendment 3
9.9% 5/12/2026
Event 3/31/2025
Lytton Laurence W 13G/A Amendment 1
5.9% 2/17/2026
Event 12/31/2025
Rosalind Advisors, Inc. 13G/A Amendment 2
9.9% 2/11/2026
Event 12/31/2025
Orin Hirschman 13G/A Amendment 1
9.8% 1/30/2026
Event 12/31/2025
Rosalind Advisors, Inc. 13G/A Amendment 1
9.9% 11/13/2025
Event 9/30/2025
Orin Hirschman 13G
9.7% 11/10/2025
Event 9/30/2025
Lytton Laurence W 13G
8.0% 9/16/2025
Event 9/10/2025
CorMedix Inc. 13D 20.0% 9/12/2025
Event 9/7/2025
Rock Springs Capital Management LP 13G
7.9% 9/12/2025
Event 9/10/2025
Rosalind Advisors, Inc. 13G
9.9% 4/11/2025
Event 3/31/2025
Nantahala Capital Management, LLC 13D/A Amendment 2
11.7% 4/3/2025
Event 3/31/2025
Nantahala Capital Management, LLC 13D/A Amendment 1
11.7% 4/2/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 57 28.2 M $29.1 M
2026 Q1 51 21.9 M $16.3 M
2025 Q4 45 20.9 M $23.8 M
2025 Q3 37 17.8 M $15.9 M
2025 Q2 33 5.28 M $2.43 M
2025 Q1 36 5.52 M $2.74 M
2024 Q4 38 4.08 M $2.14 M
2024 Q3 32 4.18 M $3.58 M
2024 Q2 37 6.34 M $5.64 M
2024 Q1 37 4.44 M $4.58 M
2023 Q4 42 5.26 M $6.83 M
2023 Q3 35 3.25 M $1.88 M
2023 Q2 29 1.06 M $1.17 M
2023 Q1 35 1.10 M $721 k
2022 Q4 38 1.48 M $3.33 M